Showing stories 1 - 10 of about 51
ADR Shares End Lower Amid Disappointing Economic Data
Novo Nordisk A/S (NVO, NOVO-B.KO), the world's top maker of insulin, said its hotly anticipated Tresiba drug may not hit the U.S.
Novo Nordisk Stock Rating Reaffirmed by Zacks (NVO)
Zacks' analyst wrote, �Novo Nordisk posted first quarter 2013 earnings of $1.94 per ADR, up 32.5% from the year-ago period.
Novo Nordisk Given Neutral Rating at Zacks (NVO)
Novo Nordisk logo Zacks reaffirmed their neutral rating on shares of Novo Nordisk (NYSE: NVO) in a report issued on Monday, Stock Ratings Network reports.